Articles with public access mandates - M.A HabraLearn more
Not available anywhere: 11
Current and future treatments for malignant pheochromocytoma and sympathetic paraganglioma
C Jimenez, E Rohren, MA Habra, T Rich, P Jimenez, M Ayala-Ramirez, ...
Current oncology reports 15, 356-371, 2013
Mandates: US National Institutes of Health
Does laparoscopic adrenalectomy jeopardize oncologic outcomes for patients with adrenocortical carcinoma?
AB Cooper, MA Habra, EG Grubbs, BK Bednarski, AK Ying, ND Perrier, ...
Surgical endoscopy 27, 4026-4032, 2013
Mandates: US National Institutes of Health
Adrenal ganglioneuroma: features and outcomes of 27 cases at a referral cancer centre
H Shawa, KM Elsayes, S Javadi, A Morani, MD Williams, JE Lee, ...
Clinical endocrinology 80 (3), 342-347, 2014
Mandates: US National Institutes of Health
Impact of 18F-FDG PET/CT on the management of adrenocortical carcinoma: analysis of 106 patients
S Takeuchi, A Balachandran, MA Habra, AT Phan, RL Bassett, ...
European journal of nuclear medicine and molecular imaging 41, 2066-2073, 2014
Mandates: US National Institutes of Health
A phase 1 study of nevanimibe HCl, a novel adrenal-specific sterol O-acyltransferase 1 (SOAT1) inhibitor, in adrenocortical carcinoma
DC Smith, M Kroiss, E Kebebew, MA Habra, R Chugh, BJ Schneider, ...
Investigational new drugs 38, 1421-1429, 2020
Mandates: US National Institutes of Health
Lung cancer-induced paraneoplastic syndromes
SCJ Yeung, MA Habra, SN Thosani
Current opinion in pulmonary medicine 17 (4), 260-268, 2011
Mandates: US National Institutes of Health
Clinical spectrum of primary adrenal lymphoma: results of a multicenter cohort study
F Majidi, S Martino, M Kondakci, C Antke, M Haase, V Chortis, W Arlt, ...
European journal of endocrinology 183 (4), 453-462, 2020
Mandates: Academy of Medical Sciences, UK, Cancer Research UK, National Institute for …
Association between new-onset hypothyroidism and clinical response in patients treated with tyrosine kinase inhibitor therapy in phase I clinical trials
MA Bilen, A Patel, KR Hess, J Munoz, NL Busaidy, JJ Wheler, F Janku, ...
Cancer chemotherapy and pharmacology 78, 167-171, 2016
Mandates: US National Institutes of Health
Epidemiological risk factors for adrenocortical carcinoma: A hospital‐based case–control study
MA Habra, MA Sukkari, A Hasan, Y Albousen, MA Elsheshtawi, ...
International journal of cancer 146 (7), 1836-1840, 2020
Mandates: US National Institutes of Health
F-18 FDG PET/CT detecting thyroid plasmacytoma after the successful treatment of gastric large B-cell lymphoma
S Shahani, A Ahmad, FH Barakat, HH Chuang, NH Fowler, JN Myers, ...
Clinical nuclear medicine 36 (4), 317-319, 2011
Mandates: US National Institutes of Health
[¹⁸F] Fluorodeoxyglucose positron emission tomography-guided therapy in metastatic adrenocortical carcinoma: an illustrative case.
HH Chuang, F Deniz, K Sircar, C Jimenez, C Rubin De Celis, CG Wood, ...
Journal of Clinical Oncology: Official Journal of the American Society of …, 2012
Mandates: US National Institutes of Health
Available somewhere: 45
Comprehensive pan-genomic characterization of adrenocortical carcinoma
S Zheng, AD Cherniack, N Dewal, RA Moffitt, L Danilova, BA Murray, ...
Cancer cell 29 (5), 723-736, 2016
Mandates: US National Institutes of Health
Adrenocortical carcinoma: clinical outcomes and prognosis of 330 patients at a tertiary care center
M Ayala-Ramirez, S Jasim, L Feng, S Ejaz, F Deniz, N Busaidy, ...
European journal of endocrinology 169 (6), 891-899, 2013
Mandates: US National Institutes of Health
Treatment with sunitinib for patients with progressive metastatic pheochromocytomas and sympathetic paragangliomas
M Ayala-Ramirez, CN Chougnet, MA Habra, JL Palmer, S Leboulleux, ...
The Journal of Clinical Endocrinology & Metabolism 97 (11), 4040-4050, 2012
Mandates: US National Institutes of Health
Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma
PC Iyer, R Dadu, M Gule-Monroe, NL Busaidy, R Ferrarotto, MA Habra, ...
Journal for immunotherapy of cancer 6, 1-10, 2018
Mandates: US National Institutes of Health
Cushing syndrome secondary to ectopic adrenocorticotropic hormone secretion: the University of Texas MD Anderson Cancer Center Experience
S Ejaz, R Vassilopoulou‐Sellin, NL Busaidy, MI Hu, SG Waguespack, ...
Cancer 117 (19), 4381-4389, 2011
Mandates: US National Institutes of Health
Clinical benefits of systemic chemotherapy for patients with metastatic pheochromocytomas or sympathetic extra‐adrenal paragangliomas: insights from the largest single …
M Ayala‐Ramirez, L Feng, MA Habra, T Rich, PV Dickson, N Perrier, ...
Cancer 118 (11), 2804-2812, 2012
Mandates: US National Institutes of Health
Insulin growth factor receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with metastatic adrenocortical carcinoma
A Naing, P Lorusso, S Fu, D Hong, HX Chen, LA Doyle, AT Phan, ...
British journal of cancer 108 (4), 826-830, 2013
Mandates: US National Institutes of Health
Phase II clinical trial of pembrolizumab efficacy and safety in advanced adrenocortical carcinoma
MA Habra, B Stephen, M Campbell, K Hess, C Tapia, M Xu, ...
Journal for immunotherapy of cancer 7, 1-9, 2019
Mandates: US National Institutes of Health
Phase 2 study of pembrolizumab in patients with advanced rare cancers
A Naing, F Meric-Bernstam, B Stephen, DD Karp, J Hajjar, JR Ahnert, ...
Journal for immunotherapy of cancer 8 (1), 2020
Mandates: US National Institutes of Health
Publication and funding information is determined automatically by a computer program